Business
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing ExpertiseSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing ExpertiseSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.\n \n \n \n \n \n \n \n\"As we continue to advance our promising portfolio of metabolic therapies, including VK2735, our potentially best-in-class GLP-1/GIP dual agonist in Phase 3 trials for obesity, we are also building the appropriate commercial capabilities to maximize the opportunities ahead. Neil is a perfect fit to lead our commercialization strategy for VK2735, including engagement with potential strategic partners, representing a key step in our preparation for commercial success,\" said Brian Lian, Ph.D., chief executive officer of Viking.Prior to joining Viking, Mr. Aubuchon was the chief commercial officer at AbCellera, where he was responsible for developing the company's commercial strategy. Prior to AbCellera, he was the global marketing lead for Amgen's general medicine early portfolio, where he developed the integrated strategy for the company's non-oncology therapeutic areas and led commercial strategy for more than ten programs, including its cardiometabolic portfolio. Before his time at Amgen, Mr. Aubuchon spent nearly 17 years at Eli Lilly in various commercial roles including, chief marketing officer in Australia, chief marketing officer in Japan, head of strategy and operations for Lilly Bio-Medicines globally, and vice president of Lilly Bio-Medicines in Japan.\"Today, novel metabolic therapeutics are revolutionizing healthcare, particularly as life-changing treatments for people with obesity, and VK2735 is uniquely positioned with its potentially best-in-class profile,\" said Mr. Aubuchon. \"I am excited to join the team and continue Viking's work to engage with stakeholders in the rapidly evolving healthcare environment to bring the company's metabolic portfolio to patients.\"About Viking Therapeutics, In...